Evidence map›Paper›PMID 38487723›Full record

ArticleFrontiers in oncology2024

Characterizing

Iulian O Ban, Alice Chabert, Thomas Guignard, Jacques Puechberty, Simon Cabello-Aguilar, Pascal Pujol, Julie A Vendrell, Jérôme Solassol

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Iulian O BanLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, Centre Hospitalier Universitaire (CHU) Montpellier, Université de Montpellier, Montpellier, France.
Alice ChabertLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, Centre Hospitalier Universitaire (CHU) Montpellier, Université de Montpellier, Montpellier, France.
Thomas GuignardDepartment of Medical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.
Jacques PuechbertyDepartment of Medical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.
Simon Cabello-AguilarLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, Centre Hospitalier Universitaire (CHU) Montpellier, Université de Montpellier, Montpellier, France.
Pascal PujolDepartment of Medical Genetics, Arnaud de Villeneuve Hospital, Montpellier, France.
Julie A VendrellLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, Centre Hospitalier Universitaire (CHU) Montpellier, Université de Montpellier, Montpellier, France.
Jérôme SolassolLaboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, Centre Hospitalier Universitaire (CHU) Montpellier, Université de Montpellier, Montpellier, France.
Centre Hospitalier Universitaire de Montpellier · FRHôpital Arnaud de Villeneuve · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Accurate identification and characterization of Large Genomic Rearrangements (LGR), especially duplications, are crucial for precise diagnosis and risk assessment. In this report, we characterized an intragenic duplication breakpoint of Methods: A 52-year-old female with triple-negative breast cancer was diagnosed with a novel Results: Duplication of exons 5 and 6 of Conclusion: Using our combined methodology, we reclassified the

Indexed as

breast cancerLGRlong-read sequencingmolecular alterationPALB2

Identifiers

PMID38487723
PMCPMC10938850
OpenAlexW4392235840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.